NCT03794336View on ClinicalTrials.gov

Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

PHASE4CompletedINTERVENTIONAL
Enrollment

1,293

Participants

Timeline

Start Date

June 29, 2019

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Alogliptin

"Pharmaceutical form: tablet~Route of administration: oral administration"

DRUG

Acarbose

"Pharmaceutical form: tablet~Route of administration: oral administration"

DRUG

Metformin

"Pharmaceutical form: tablet~Route of administration: oral administration"

DRUG

Aspirin

"Pharmaceutical form: tablet~Route of administration: oral administration"

Trial Locations (1)

Unknown

CHINA, China

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY